

1 **Methylglyoxal-derived hydroimidazolone, MG-H1, increases food**
2 **intake by altering tyramine signaling via the GATA transcription factor**
3 **ELT-3 in *Caenorhabditis elegans***

4 Muniesh Muthaiyan Shanmugam¹, Jyotiska Chaudhuri¹, Durai Sellegounder¹, Amit Kumar
5 Sahu¹, Sanjib Guha¹, Manish Chamoli¹, Brian Hodge¹, Charis Roberts², Gordon Lithgow¹,
6 Richmond Sarpong² and Pankaj Kapahi^{1,3}

7
8 ¹The Buck Institute for Research on Aging, 8001 Redwood Boulevard, Novato, CA 94945, USA.

9 ²Department of Chemistry, University of California, Berkeley, CA 94720, USA.

10 ³Department of Urology, University of California, 400 Parnassus Avenue, San Francisco, CA
11 94143, USA.

12 Correspondence: pkapahi@buckinstitute.org

13

14

15

16

17

18

19

20

21 **ABSTRACT**

22 The Maillard reaction, a chemical reaction between amino acids and sugars, is exploited
23 to produce flavorful food almost everywhere, from the baking industry to our everyday life.
24 However, the Maillard reaction also takes place in all cells, from prokaryotes to eukaryotes,
25 leading to the formation of Advanced Glycation End-products (AGEs). AGEs are a heterogeneous
26 group of compounds resulting from the irreversible reaction between biomolecules and α -
27 dicarbonyls (α -DCs), including methylglyoxal (MGO), an unavoidable byproduct of anaerobic
28 glycolysis and lipid peroxidation. We previously demonstrated that *Caenorhabditis elegans*
29 mutants lacking the *glod-4* glyoxalase enzyme displayed enhanced accumulation of α -DCs,
30 reduced lifespan, increased neuronal damage, and touch hypersensitivity. Here, we demonstrate
31 that *glod-4* mutation increased food intake and identify that MGO-derived hydroimidazolone, MG-
32 H1, is a mediator of the observed increase in food intake. RNA-seq analysis in *glod-4* knockdown
33 worms identified upregulation of several neurotransmitters and feeding genes. Suppressor
34 screening of the overfeeding phenotype identified the *tdc-1*-tyramine-*tyra-2/ser-2* signaling as an
35 essential pathway mediating AGEs (MG-H1) induced feeding in *glod-4* mutants. We also identified
36 the *elt-3* GATA transcription factor as an essential upstream factor for increased feeding upon
37 accumulation of AGEs by partially regulating the expression of *tdc-1* and *tyra-2* genes. Further,
38 the lack of either *tdc-1* or *tyra-2/ser-2* receptors suppresses the reduced lifespan and rescues
39 neuronal damage observed in *glod-4* mutants. Thus, in *C. elegans*, we identified an *elt-3* regulated
40 tyramine-dependent pathway mediating the toxic effects of MGO and associated AGEs.
41 Understanding this signaling pathway is essential to modulate hedonistic overfeeding behavior
42 observed in modern AGEs rich diets.

43

44 **Keywords:** Feeding, Advanced Glycation End-products (AGEs), *glod-4*, MG-H1, tyramine, GATA
45 transcription factor, *elt-3*, *tyra-2*, *ser-2*, *C. elegans*, neuronal damage, pharyngeal pumping.

46 INTRODUCTION

47 Processed modern diets enriched with Advanced Glycation End-products (AGEs), formed
48 by Maillard reaction, are tempting to eat but at the same time deleterious for health [1] [2] [3]. In
49 1912, a French Chemist L.C. Maillard, reported a reaction between glucose and glycine upon
50 heating resulting in the formation of brown pigments [4]. Later the covalent bonds formed between
51 carbohydrates and proteins during heating in a non-enzymatic browning reaction was named the
52 Maillard reaction [5] [6]. Glycation is a part of the Maillard reaction, or browning of food, during
53 cooking which enhances the taste, color, and aroma of the food to make it more palatable [4] [7].
54 Maillard reaction has revolutionized the food industry by playing an important role in food
55 chemistry [8]; however, this reaction also results in the formation of adverse AGEs as well as toxic
56 byproducts and one of the well-studied toxic byproduct is acrylamide [9] [10] [11].


57 Apart from food, AGEs are endogenously produced in cells when either reducing glucose
58 or α -dicarbonyl compounds (α -DCs) (such as glyoxal (GO), methylglyoxal (MGO), 3-
59 deoxyglucosone (3DG), etc.) and non-enzymatically react with biomolecules. α -DCs are
60 unavoidable byproducts of cellular metabolisms, such as glycolysis and lipid peroxidation. AGEs
61 include GO derivatives such as carboxymethyl lysine (CML) and glyoxal lysine dimer (GOLD).
62 AGEs derived from MGO include hydroimidazolone (MG-H1), carboxyethyl lysine (CEL), and
63 methylglyoxal lysine dimer (MOLD), and 3DG derivatives include 3-deoxyglucosone-derived
64 imidazolium cross-link (DOGDIC), Pyrraline, etc. [12] [13] [1] [14]. The glyoxalase system utilizes
65 glyoxalases enzymes, Glo1 and Glo2, and reduced glutathione (GSH) to detoxify α -DCs stress,
66 especially MGO to lactate, in cytosol and nucleus. Differential expression levels of glyoxalases
67 are reported in various disease conditions such as diabetes, hypertension, neurodegenerative
68 disorders, anxiety disorders, infertility, cancer, etc., suggesting their role in exacerbating their
69 pathogenesis [15]. Glo1 has been linked with several behavioral phenotypes, such as anxiety,
70 depression, autism, and pain, among other mental illnesses [16]. Also, we have previously

71 demonstrated increased neuronal damage in the *C. elegans glod-4* glyoxalase mutant model,
72 which is shown to accumulate high levels of α -DCs and AGEs [17]. AGEs accumulate in long-
73 lived proteins, such as collagen and lens crystallins [18]; further, quantifying the glycated form of
74 hemoglobin (HbA1c) is utilized as a biomarker in diabetes [19]. It is vital to notice that AGEs are
75 strongly implicated in aging and associated diseases such as obesity, diabetes,
76 neurodegeneration, inflammation, cardiomyopathy, nephropathy, and other diseases [20] [1] [21].
77 Especially, neurodegenerative diseases have demonstrated a strong correlation between AGEs
78 levels and pathogenesis.

79 Overconsumption of food and excessive availability of cheap, highly processed foods
80 lacking nutritional qualities contribute to the obesity pandemic. Obesity leads to other
81 complications like diabetes, hypertension, cancers, cardiovascular, inflammatory, and
82 neurodegenerative disorders, among other non-communicable chronic diseases [22] [23] [24] [25]
83 [26] [27] [28] [29]. Although identifying genetic loci linked to obesity improves treatment options
84 [30], exploring other signaling pathways modulating increased feeding behavior and obesity is
85 essential. Here we report that loss of glyoxalase system increased feeding behavior in *C. elegans*
86 mediated by accumulation of AGEs. We also identified the mechanism for the observed
87 phenotype and found that MG-H1 acts via the *elt-3* GATA transcription factor to partially regulate
88 the expression of *tdc-1*, an enzyme that biosynthesis tyramine neurotransmitter, and its receptor,
89 *tyra-2* as well as *ser-2*, to mediate adverse effects of AGEs such as increased feeding, reduced
90 lifespan, and neuronal damages. This study is the first to identify the signaling pathway mediated
91 by specific AGEs molecules downstream of MGO (such as MG-H1) to enhance feeding and
92 neurodegeneration. Our study emphasizes that AGEs accumulation is deleterious and enhances
93 disease pathology in different conditions, including obesity and neurodegeneration. Hence,
94 limiting AGEs accumulation is relevance to the global increase in obesity and other age-
95 associated diseases.

96 **RESULTS**

97 **AGEs increases food intake and food-seeking behavior in *C. elegans***



98

99 Figure 1: MG-H1 increases pharyngeal pumping and feeding in *C. elegans*. (A) Quantification of
100 pharyngeal pumping (#/30 sec) in N2 (wt) and *glod-4 (gk189)* mutant at different stages of
101 adulthood. (B) Food clearance assay in N2 (wt) and *glod-4 (gk189)* mutant after 72 hours of
102 feeding. (C) Quantification of pharyngeal pumping (#/30 sec) in N2 (wt) after treatment, with either
103 150 μ M of Arginine (control) or MG-H1. (D) Food clearance assay in N2 (wt) worms after treatment
104 for 72 hours with either 150 μ M of Arginine (control) or MG-H1. (E) Quantification of pharyngeal
105 pumping with different concentrations of MG-H1. (F) Food racing assay in N2 (wt) and *glod-4*
106 (*gk189*) at different stages of adulthood towards OP50-1. (G) Food racing assay in N2 (wt) and
107 *glod-4 (gk189)* towards OP50-1 mixed with MG-H1 vs OP50-1 mixed with MGO. Student t-test
108 for A, B, C, E & F. One way ANOVA with Fisher's LSD multiple comparison test for D & G. *
109 $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$ and **** $p < 0.0001$. Error bar \pm SD.


110

111 Our initial observations revealed that *glod-4* glyoxalases enzyme mutants exhibit a
112 significantly enhanced pharyngeal pumping than wild-type N2 animals (Figures 1A). This increase
113 in pharyngeal pumping was consistent from day 1 (young adult, post-65 hours of timed egg-laying)
114 till day 3 of adulthood (Figure 1A). We performed a food clearance assay to validate whether
115 increased pharyngeal pumping was also accompanied by enhanced food intake (Figure 1B +
116 Figure Suppl. 1A) and found increased bacterial clearance after 72 hours in *glod-4* mutants.
117 Further, treatment with serotonin resulted in increased bacterial clearance in both wild-type N2
118 worms and *glod-4* mutants (Figure Suppl. 1B+1C), suggesting that AGEs mediated increased
119 pharyngeal pumping is independent of the serotonin signaling [31]. These preliminary
120 observations lead to the hypothesis that enhanced feeding in *glod-4* mutant worms is either
121 mediated by endogenous accumulation of α -DCs or AGEs characterized previously [17] [32] [33].
122 To this end, we found that MG-H1 and CEL as potential MGO-derived AGEs to cause increased
123 feeding. Just feeding MGO was not sufficient to increase the pharyngeal pumping rate (Figure

124 Suppl. 1D). Time course analysis in wild-type N2 worms treated with MG-H1 showed that 24 hrs
125 of MG-H1(150 μ M) treatment was enough to increase pharyngeal pumping significantly (Figure
126 1C). A significant increase in bacterial clearance was observed after 72 hours (Figure 1D). In
127 addition, we also demonstrated that MG-H1 regulates pharyngeal pumping rate in a dose-
128 dependent manner (Figure 1E). Since MG-H1 is the product of arginine modification by MGO, we
129 used arginine as a negative control for our MG-H1 treatment. We did not observe a significant
130 difference between worms treated with arginine versus water versus PBS (Figure Suppl. 1E). In
131 addition to food consumption, *glod-4* mutant exhibited a significantly increased preference
132 towards food source OP50-1 at day 1 and day 3 of adulthood compared to wild-type N2 worms
133 (Figure 1F + Figure Suppl. 1F). Furthermore, we noticed that wild-type N2 worms preferred
134 exogenous MG-H1 compared to MGO when provided with bacterial food source *E. coli* OP50-1.
135 We did not observe this phenotype in the *glod-4* mutant background (Figure 1G), suggesting that
136 MG-H1 and *glod-4* null mutation increases feeding by overlapping mechanism.

137 **Tyramine regulates MG-H1 mediated feeding behavior via G-protein-coupled receptors** 138 **(GPCRs) TYRA-2 and SER-2**

139 Next, we sought to elucidate how MG-H1 increases the feeding behavior in worms. We
140 performed an unbiased RNA sequencing approach to analyze the global transcriptome profile
141 between control and *glod-4* knockdown worms (Suppl. File). Gene set enrichment analysis
142 showed that the functional category of genes regulating feeding behavior was significantly
143 upregulated in *glod-4* knockdown worms (> 2-fold enrichment score) (Figure 2A, red * marked
144 GO category). This analysis supports our above observation that *glod-4* mutants have an altered
145 feeding rate. Previous studies in *C. elegans* have documented the role of neurotransmitters in *C.*
146 *elegans* feeding behavior [34] [35] [36] and we observed differential expression of 66
147 neurotransmitters and feeding genes (which comprises ~19% of the total feeding and
148 neurotransmission-related genes in *C. elegans*) (Figure 2B).




150 Figure 2: Role of *tdc-1* - tyramine receptors in mediating the MG-H1 induced feeding behavior.
151 (A) Gene ontology analysis of differentially expressed genes in *glod-4* RNAi worms. (B)
152 Differential expression of 66 neurotransmitters and feeding genes in *glod-4* RNAi background.
153 (C) The flowchart shows the pathway of biogenic amine synthesis, which functions as a
154 neurotransmitter. (D) Quantification of pharyngeal pumping in N2 (wt) and *tdc-1* mutant worms
155 after 24 hrs of treatment of MG-H1. (E) Quantification of pharyngeal pumping in N2 (wt), *tdc-1*,
156 *glod-4*, and *tdc-1;glod-4* double mutants. (F & G) Quantification of pharyngeal pumping in N2 (wt),
157 *tyra-2*, *ser-2*, *tyra-2;glod-4* and *ser-2;glod-4* mutants. One-way ANOVA for D-G. * $p < 0.05$, **
158 $p < 0.01$, *** $p < 0.005$ and **** $p < 0.0001$. Error bar \pm SD.

159

160 We next tested the involvement of these neurotransmitter genes in regulating MG-H1
161 mediated feeding behavior, and systematically analyzed MG-H1-induced feeding in the
162 background of genetic mutants limited in producing different biogenic amines and
163 neurotransmitters in *C. elegans* (Figure 2C + Figure Suppl. 2A). We found that mutation in *tdc-1*,
164 the gene involved in synthesizing neurotransmitter tyramine, significantly suppressed the
165 enhanced feeding phenotype in MG-H1 treated animals (Figure Suppl. 2A + Figure 2D). We also
166 confirmed suppression of increased feeding rate in *tdc-1;glod-4* double mutant animals compared
167 to *glod-4* (Figure 2E). Next, we checked putative receptors for tyramine that could potentially
168 mediate downstream signaling. Receptors for tyramine and octopamine are well-studied G-
169 protein-coupled receptors (GPCRs) [37] [38]. We screened seven GPCRs to identify the potential
170 link in regulating tyramine-mediated increased feeding rate exhibited by *glod-4* mutant worms or
171 MG-H1-treated worms. Observed results showed a mutation in *ser-2* and *tyra-2* suppresses
172 enhanced feeding in MG-H1 treated animals (Figure Suppl. 2B). A similar reversal of feeding
173 phenotype was observed in *tyra-2;glod-4*, and *ser-2;glod-4* double mutant strains (Figure 2F+2G).
174 Our findings support the idea that MG-H1 induced overfeeding is mediated by tyramine signaling.

175 **GATA transcription factor *elt-3* acts upstream of *tdc-1* to regulate MG-H1-mediated feeding**
 176 **behavior**



177


178 Figure 3: Role of *elt-3* transcription factor in regulating MG-H1 induced feeding in *C. elegans*. (A)
179 List of transcription factors identified by motif analysis. (B) Flowchart demonstrating the method
180 of identification of transcription factors. (C) Quantification of pharyngeal pumping after treatment
181 with either Arginine or MG-H1 in *elt-3* mutants. (D) Quantification of pharyngeal pumping in N2
182 (wt), *glod-4*, *elt-3*, and double mutant worms. (E) Quantification of *elt-3* target genes in *elt-3*
183 mutant worms. (F) Quantification of *elt-3* and tyramine pathway gene expressions in wild-type N2
184 (wt) worms after MG-H1 treatment. Horizontal dotted line indicate the normalized expression
185 levels of genes in N2 (wt) and untreated control in E and F, respectively. One-way ANOVA for
186 C+D. Student's t-test for E+F. * p<0.05, ** p<0.01, *** p<0.005 and **** p<0.0001. Error bars ±SD.

187

188 To check for putative transcription factors (TFs) that could regulate the 66 differentially
189 expressed genes in *glod-4* knockdown worms, we performed a motif-enrichment analysis (based
190 on available ChIP-Seq data) (Figure 3A+3B). We chose the top five TFs (with a threshold of
191 >18.75% target sequence match for TF- binding motif) for further screening. We knocked down
192 each of the five TFs individually and checked for the rescue of the feeding behavior in worms
193 exposed to 100 μM MG-H1 (Figure Suppl. 3A). Knocking down *pha-4* and *elt-3* suppressed the
194 increase in pharyngeal pumping induced by MG-H1 treatment (Figure Suppl. 3A + Figure 3C).
195 The *pha-4* gene is crucial for pharynx development, and loss of *pha-4* results in a morphological
196 defect of the pharynx [39] [40]. Therefore, we chose to follow the results from *elt-3* knockdown
197 worms with genetic mutants. Analysis of pharyngeal pumping in *elt-3;glod-4* double mutant
198 showed that *elt-3* is essential to increase pharyngeal pumping observed in *glod-4* mutant worms
199 (Figure 3D). To determine the role of *elt-3* in the tyramine signaling pathway, we performed a
200 HOMER (Hypergeometric Optimization of Motif EnRichment) analysis and identified the binding
201 site of *elt-3* on the *tdc-1* promoter, which suggested *elt-3* may potentially regulate *tdc-1* expression
202 levels (Figure Suppl. 3B). This was further validated by reduced expression of *tdc-1* mRNA levels

203 in the *elt-3* mutant worms (Figure 3E). Next, to check if the *elt-3* expression is changed on
 204 exposure to MG-H1, we treated wild-type N2 worms with MG-H1 and quantified mRNA levels of
 205 *elt-3*. We observed a moderate but significant increase in the *elt-3* expression (Figure 3F).
 206 Although *tdc-1* and *tyra-2* did not change significantly, expression levels of other tyramine
 207 receptors, *tyra-3* and *ser-2*, increased significantly after MG-H1 exposure (Figure 3F). Note that
 208 *ser-2* is necessary to mediate the increased pharyngeal pumping (Figure 2G). Together these
 209 experiments identified a key role for *elt-3* in tyramine-induced feeding increase in response to
 210 MG-H1.

211 **Absence of tyramine rescues α -DC mediated pathogenic phenotypes**



212

213 Figure 4: Suppression of *glod-4* phenotypes in *tdc-1;glod-4* double mutant. (A) Survival assay
214 with N2 (wt), *tdc-1*, *glod-4*, and *tdc-1;glod-4* double mutants. (B) Survival assay with N2 (wt), *tyra-*
215 *2*, *glod-4*, and *tyra-2;glod-4* double mutants. (C) Survival assay with N2 (wt), *ser-2*, *glod-4*, and
216 *ser-2;glod-4* double mutants. (D) Image of worm neurons showing neuronal damage at day 8 of
217 adulthood. (E) Quantification of neuronal damage with pan-neuronal GFP marker in *glod-4* vs.
218 *tdc-1;glod-4* double mutants. Scale Bar – 10 μ m. Log-rank (Mantel-Cox) test for survival assays.
219 One-way ANOVA for (E). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$ and **** $p < 0.0001$. Error bar \pm SD.

220

221 Accumulation of α -DC in *glod-4* mutants results in pathogenic phenotypes including
222 neurodegeneration and shortening of lifespan [17]. Here, chronic accumulation of MGO leads to
223 the build-up of AGEs, thereby increasing feeding in *glod-4* worms (Figure 1). To test whether the
224 pathogenic phenotypes exhibited by *glod-4* mutants result due to enhanced feeding, we
225 compared the lifespan between wild-type N2 and *glod-4* worms in the genetic mutants that lack
226 tyramine. The lifespan of *glod-4* was significantly increased upon inhibition of tyramine signaling
227 in the *tdc-1;glod-4* double mutation (Figure 4A). In addition to rescuing lifespan and feeding rate,
228 the lack of tyramine also resulted in the partial but significant rescue of neuronal damage in *glod-*
229 *4* animals (Figure 4D+E).

230 Next, we tested if the absence of *tyra-2* and *ser-2* could also rescue the shortened lifespan
231 of *glod-4* mutants. Lifespan increased significantly in the absence of either *tyra-2* or *ser-2* in
232 double-mutant animals (Figure 4B+4C).

233

234 **DISCUSSION**

235 Our observation that *glod-4* mutants run out of bacterial lawn faster than wild-type N2
236 animals during routine maintenance led to the elucidation of a novel signaling pathway that

237 mediates AGEs-induced feeding behavior in *C. elegans*. Glyoxalases are enzymes involved in
238 the detoxification of α -dicarbonyls, and we have previously characterized *glod-4* mutant, which
239 lacks one of the glyoxalase enzymes, to accumulate increased levels of α -dicarbonyls and thereby
240 AGEs [17]. In this study, using genetic mutants, synthesized AGEs, and functional genomics, we
241 elucidate that AGEs (especially MG-H1) regulate feeding through tyramine signaling regulated by
242 GATA transcription factor ELT-3. Also, MG-H1-induced hyper-feeding is independent of
243 serotonin-mediated hyper-feeding [31] in *C. elegans* (Figure Suppl. 1B+1C). As both exogenous
244 feeding of MG-H1 and the *glod-4* mutant, which enhances AGEs, led to increased feeding, we
245 hypothesize that increased accumulation of AGEs is a potential stimulator of binge feeding. Thus,
246 we studied changes in pumping rate by exogenous administration of MGO and AGEs. As
247 previously reported by Ravichandran *et al.* 2018, MGO treatment did not change the pumping
248 rate; however, MG-H1 and CEL increased the pumping rate in wild-type N2 worms (Figure Suppl.
249 1D) [41]. Further, a recent study demonstrated that treatment with sugar-derived AGE-modified
250 Bovine Serum Albumin (BSA) accelerated the pharyngeal pumping rate[42]. In our study, we
251 demonstrate that endogenous production and accumulation of AGEs via genetic mutation
252 increase feeding and adversely affect lifespan.

253 Our detailed investigation of the time-dependent increase in pumping rate after MG-H1
254 treatment indicates a more robust and highly significant increase after 24 hours of treatment
255 (Figure 1C). It is well established that AGEs are formed during cooking, browning the food during
256 dry heating, making the food more appetizing [14]. Further, feeding is a multisensorial process
257 regulated by several signaling pathways subjected to evolutionary adaptations [9]. Thus, we
258 wanted to analyze the changes in sensory behavior of *C. elegans* induced by either endogenous
259 accumulation of AGEs or by exogenous administration of MG-H1 with the food. Since the *glod-4*
260 mutant lacks a glyoxalase system to detoxify methylglyoxal and leads to the accumulation of
261 AGEs, the MG-H1 mediated signaling pathway can be responsible for the increased

262 chemoattraction of *glod-4* mutant worms to food source OP50-1 (Figure 1F). It can be explained
263 that including MG-H1 in bacterial lawn increased chemoattraction of wild-type N2 worms towards
264 food, resulting in increased feeding of palatable MG-H1-mixed bacterial food OP50-1 (Figure 1G).
265 However, unlike wild-type N2 worms, exogenous MG-H1 treatment had no further increase in the
266 feeding rate or chemoattraction of *glod-4* mutant worms (Figure 1D+1G), indicating the maximum
267 sensory modulation attained by the endogenous accumulation of MG-H1 in the *glod-4* mutant.
268 Although our screening identified CEL, a lysine derived adduct of MGO, as another AGEs
269 increasing the food intake, a detailed analysis is necessary to conclude the effect of CEL on
270 feeding behavior (Figure Suppl. 1D).

271 We utilized RNA-seq data from *glod-4* knockdown worms to identify the novel signaling
272 pathway that mediates AGEs-induced feeding in *C. elegans*. Since *glod-4* knockdown data are
273 enriched with several genes regulating the synthesis of neurotransmitters and feeding (Figure
274 2A+2B), we performed suppression screening in mutant worms for genes involved in synthesizing
275 biogenic amine neurotransmitters after MG-H1 treatment (Figure 2C and Figure Suppl. 2A+2B).
276 Thus, our screen identified *tdc-1*, involved in the biosynthesis of tyramine, and tyramine receptors
277 (*tyra-2* and *ser-2*) to mediate AGEs induced increased pharyngeal pumping (Figure 2D-2G) and
278 Figure Suppl. 2). Tryptophan and tyrosine are the substrates for the synthesis of biogenic amines
279 that have been implicated in modulating a wide array of behaviors in *C. elegans* [35, 43]. Tyrosine
280 to Tyramine conversion in the presence of the enzyme tyrosine decarboxylase (TDC-1) followed
281 by tyramine β -hydroxylase (TBH-1) is crucial for the synthesis of neurotransmitters tyramine and
282 octopamine, respectively [43, 44]. Previous studies have shown the role of tyramine and its
283 receptor (*ser-2*) in regulating feeding and foraging behavior in *C. elegans* [31] [45] [44] [46].
284 Further, the *tyra-2* receptor is expressed in MC and NSM pharyngeal neurons and discussed to
285 potentially regulate pharyngeal pumping [31] [47]. Especially, tyramine has been shown to reduce
286 pharyngeal pumping when applied exogenously to the worms [31]. Supporting previous findings

287 [31], our observation shows increased pharyngeal pumping in *tyra-2* and *ser-2* single mutant
288 worms (Figure 2F+2G); at the same time, *tdc-1* single mutants did not increase pumping (Figure
289 2E). Converse to our observation of *tyra-2* and *ser-2* single mutants, Greer *et al.* 2008 did not find
290 any difference in the pumping rate of *tyra-2* and *ser-2* single mutants compared to wild-type N2
291 worms. However, the same study reported no changes in the pumping rate of *tdc-1* single mutant,
292 similar to our results [44], which is also demonstrated by Li et al. 2012 [46]. Interestingly, double
293 mutants of either *tdc-1* or its receptors (*tyra-2*-partial rescue and *ser-2*) with *glod-4* mutant
294 significantly suppress the increased pharyngeal pumping observed in either *glod-4* or *tyra-2* or
295 *ser-2* single mutants (Figure 2E-2G). It is to be noted that only two interneurons, namely RIM and
296 RIC, uv1 cells near vulva and gonadal sheath cells [43] express the *tdc-1* gene, which is involved
297 in the biosynthesis of tyramine; however, receptors of tyramine are expressed in distant tissues
298 explaining an endocrine activity for tyramine neurotransmitter [31] leading to the multi-pathway
299 mode of action to exert differential response which should be elucidated in future. Since *ser-3*
300 mutant worms did not suppress the pumping (Figure Suppl. 2B) and *ser-3* has been demonstrated
301 to be a receptor for octopamine [31], we conclude that octopamine is not responsible for mediating
302 MG-H1 induced feeding in *C. elegans*.

303 Our suppressor screen for the upstream effector of the *tdc-1*-tyramine-*tyra-2/ser-2*
304 pathway that mediates MG-H1-induced increased feeding identified the *elt-3* transcription factor
305 (Figure 3C+3D). Thus, we examined whether *elt-3* TF regulates the *tdc-1*, *tyra-2*, or *ser-2*. Our
306 analysis revealed that in *elt-3* mutant worms, *tdc-1* and *tyra-2* genes are significantly reduced
307 (Figure 3E), concluding that *elt-3* TF regulates tyramine biosynthesis and receptor genes. In favor
308 of the data, HOMER analysis identified *tdc-1* gene is potentially regulated by *elt-3* TF (Figure
309 Suppl. 3B). Although *elt-3* TF is predominantly expressed in hypodermal cells, its expression is
310 also reported in the pharyngeal-intestinal valve, intestine, few neurons (head neurons and
311 mechanosensory PVD neuron), etc. (Wormbase.org). In accordance with *elt-3* expression in PVD

312 neurons and head neurons, *tyra-2* is also expressed in PVD neuron [47] and *tdc-1* in RIM and
313 RIC head interneurons, respectively, suggesting a possible direct/partial regulation of *tyra-2* and
314 *tdc-1* expression by *elt-3*. Also, the *tyra-2* expression has been reported in pharyngeal MC
315 neurons, which directly regulate pharyngeal pumping, [47] suggesting direct endocrine action of
316 tyramine. Similarly, *ser-2* is expressed in pharyngeal muscle segment cells [45, 46, 48]. Though
317 the *ser-2* expression is unchanged in *elt-3* mutant worms, *ser-2* expression is significantly
318 increased in MG-H1 treated wild-type N2 worms (Figure 3F). Although the mechanism of MG-H1
319 induced expression of *ser-2* is unclear, it is evident that the *ser-2* genetic mutant can suppress
320 the increased feeding in the *glod-4* mutant (double mutants) (Figure 2G), demonstrating an
321 important role of the SER-2 receptor in mediating the MG-H1 induced feeding via tyramine.
322 Further, *elt-3* expression levels significantly increased after MG-H1 treatment. Altogether our data
323 strongly suggest the role of *elt-3-tdc-1-tyramine-tyra-2/ser-2* pathway in mediating enhanced
324 feeding. Finally, it is essential to note that a few genes upregulated in the *glod-4* knockdown RNA-
325 seq dataset have also been significantly upregulated after MG-H1 treatment, such as *ser-2* and
326 *tyra-3*, validating that MG-H1 is a critical player in mediating adverse phenotypes observed in
327 *glod-4* mutant worms.

328 Previously, we have demonstrated reduced lifespan, hyperesthesia, and accelerated
329 neurodegeneration-like phenotypes observed in diabetic conditions, caused by excessive
330 accumulation of α -dicarbonyls in *glod-4* mutant worms [17]. Lack of dicarbonyl detoxification by
331 glyoxalases enzymes in *glod-4* mutant worms should result in the accumulation of AGEs, which
332 at sufficient concentration act as signaling molecules to modulate the feeding behavior (Figure 1)
333 by causing differential gene expression (Figure 2). The increased amount of dicarbonyl stress,
334 thereby AGEs, is observed in several systemic diseases such as obesity, diabetes, cardiovascular
335 and neurodegenerative diseases, among other age-associated diseases [1]. In diabetic patients,
336 three times higher plasma levels of MGO have been reported, and is a leading cause of

337 neuropathic pain [49] [50] [51]. The earlier reports in the literature show that the dicarbonyl levels
338 correlate with diabetic complications. One of the major risk factors for diabetes is obesity [52],
339 which is caused by overfeeding. Thus, exploring the regulatory pathways of feeding is essential
340 to understand better and identify ways to modulate feeding behavior.

341 Here, we show that AGEs can modulate feeding behavior in evolutionary primitive model
342 organisms, and it will be worth exploring this pathway in mammals. The transcription factor *elt-3*
343 belongs to the GATA transcription factor family [53] Shobatake *et al.* 2018 report that GATA 2
344 and 3 transcription factors induce the expression of appetite regulator genes such as POMC and
345 CART [54]. With the easy availability and unlimited access to modern-day processed food
346 enriched in sugars and AGEs resulting in overeating, a significant cause of obesity pandemic, it
347 is necessary to explore signals regulating feeding. Importantly, our study shows exogenous
348 treatment with MG-H1 increases feeding in worms (Figure 1C+1D), indicating that a high AGEs
349 diet in our day-to-day life can modulate feeding behavior in humans. It is well known that food
350 cooked by grilling, broiling, roasting, searing, and frying accelerates the formation of AGEs in
351 food; thus, methods are explored to cook food with fewer AGEs accumulation [55]. Further,
352 increased caloric intake and changes in eating habits have been reported in a behavioral variant
353 of Frontotemporal Dementia (FTP) [56] and medication of antipsychotic drugs [57].

354 Finally, we show that a lack of *tdc-1*-tyramine signaling rescues *glod-4* mutant phenotypes
355 (lifespan and neuronal damage) (Figure 4). A strong association between worsening PD
356 phenotypes with increased aggregation of α -synuclein and specific sites of increased glycation
357 has been demonstrated in different genetic models with increased AGEs [58]. Thus, it will be
358 interesting to investigate the role of the *tdc-1*-tyramine pathway in modulating pathways
359 enhancing neurodegeneration and feeding. Recent research identified neurodegenerative
360 diseases to be influenced by metabolism [59, 60] and *glod-4* mutants demonstrate increased
361 neuronal damage, decreased lifespan, and increased feeding. Thus, it is essential to investigate

362 the balance between energy metabolism to identify critical pathways to modulate the outcome of
363 neurodegenerative diseases.

364

365 **MATERIALS AND METHODS**

366 **Strains**

367 Strains were either obtained from *Caenorhabditis* Genetic Center (CGC), Minneapolis,
368 USA or National Bioresource Project, Tokyo, Japan and the following strains were used: N2 (wt),
369 VC343 *glod-4(gk189)*, VC143 *elt-3(gk121)*, MT13113 *tdc-1(n3419)*, *tyra-2(tm1846)*, RB1690 *ser-*
370 *2(ok2103)*, MT9455 *tbh-1(n3247)*, CB1112 *cat-2(e1112)*, MT15434 *tph-1(mg280)*, DA1814 *ser-*
371 *1(ok345)*, RB1631 *ser-3(ok2007)*, RB745 *ser-4(ok512)*, VC125 *tyra-3(ok325)*, and OH438
372 *otls117[unc-33p::gfp + unc-4(+)]*. Mutant strains are crossed to get the double mutants *elt-3;glod-*
373 *4*, *tdc-1;glod-4*, *tyra-2;glod-4*, *ser-2;glod-4*, and *glod-4;unc-33p::gfp*. RNAi clones were obtained
374 from Ahringer's RNAi feeding library and the following were used: *pha-4*, *ces-1*, *elt-3*, *lin-39*, *egl-*
375 *5*, and *tdc-1*.

376 **Growth and maintenance**

377 Worms were cultured at 20°C for at least two generations on standard NGM agar plates
378 seeded with 5X *Escherichia coli* OP50-1 bacterial strain (Broth culture of OP50-1 was cultured
379 overnight at 37 °C at 220 rpm), which was propagated at RT for two days. For feeding RNAi
380 bacteria, synchronized L1 larvae were transferred to NGM plates containing 3 mM of isopropyl β-
381 D-1-thiogalactopyranoside/IPTG (referred to as RNAi plates) seeded with 20X concentrated
382 HT115 bacteria (cultured overnight at 37 °C at 220 rpm), carrying the desired plasmid for RNAi of
383 a specific gene or bacteria carrying empty vector pL4440 as control and allowed to grow on plates
384 for 48 hrs. For drug assays, synchronized young adult worms (60 to 65 hrs from egg-laying) were
385 transferred to NGM plates (with or without IPTG) with 20X HT115 RNAi bacteria or 5X OP50-1

386 bacteria (respectively), which are freshly overlaid by the desired drug (or vehicle control) that
387 was air-dried and diffused. Final drug concentrations were calculated considering the total media
388 volume on the NGM plates.

389 Note: For *glod-4* mutant animals, we found that the pathogenic phenotypes discussed in this
390 paper are contingent on strictly maintaining an *ad-libitum* feeding regimen. Hence, care was
391 taken not to allow the animals to starve by maintaining a low worm-to-bacteria ratio and
392 transferring to fresh plates frequently (at least once every two days).

393 **Pharyngeal pumping assay**

394 *C. elegans* pharyngeal pumping was measured using a Leica M165 FC stereomicroscope
395 utilizing a modified previously established method [61]. Grinder movement in the terminal bulb
396 was used as a read-out for the pumping rate phenotype. Pharyngeal pumping was recorded using
397 a Leica M165 FC microscope; thus, obtained movies were played at X0.25 times the original
398 speed and a manual counter was used to count the number of pumps for 30 sec. For quick
399 pumping screening (pumping data in the supplemental figures), the pumping rate was counted in
400 real-time for 30 seconds using a stopwatch and a manual counter focusing the grinder using an
401 Olympus SZ61 stereomicroscope. 10 – 30 animals were counted per biological repeat and 2 to 3
402 repeats were obtained for each experiment and pumping data from all the repeats were combined
403 for the presentation of data in the figures. At least one biological replicate was counted blind.
404 Animals that did not pump during the recording time were eliminated from the analysis as well a
405 few outliers were identified using the Gaussian distribution curve. Under exogenous drug
406 treatment, animals were incubated in the drug at least 18-24 or until 48 hours before measurement
407 of the pump rate. The drugs were overlaid on the NGM plate containing bacterial lawn and air
408 dried before the addition of worms.

409 **Food clearance assay**


410 Food clearance assay was performed following minor modification to established protocol
411 by Wu et al. [62]. In brief, synchronized 20–25 L3-L4 stage worms were washed twice in S basal
412 then once with S complete medium and transferred to a 96 well plate containing 160 μ l assay
413 medium (S-complete medium, growth-arrested OP50–1 at final OD 0.8 (at 600 nm), antibiotics,
414 FuDR and either 150 μ M Arginine or MG-H1 or 5 mM serotonin). Initial bacterial density was
415 measured by obtaining OD at 600 nm. Following the indicated number of hours, bacterial density
416 was measured at OD600 after a brief and gentle mixing using a multichannel pipet. For each
417 experimental data point, at least six wells were measured (at least 120-150 worms in total), with
418 the results shown being representative of at least two to three independent assays. The relative
419 food intake was determined by the change in OD for each well, normalized to the number of
420 worms. Under these conditions, ample OP50-1 was available for feeding throughout the analysis,
421 and worms were maintained in the same wells for the entire duration of the experiment.

422 **Food race assay**

423 The food race assay to evaluate *C. elegans* choice or attraction for a specific diet, a
424 chemosensory behavior, was performed utilizing a previously established protocol [63]. For this
425 assay, synchronized adult worms (50 per race) were spotted on a 60 mm NGM agar plate, freshly
426 seeded with *E. coli* OP50-1 (with or without drug) approximately 2 cm from the edge of the Petri
427 plate. Adult animals were aliquoted on the plate diametrically opposite to the food source to
428 estimate the percentage of worms that reached the food source within 30 minutes. An illustration
429 of the food-race assay has been provided (Figure Suppl. 1F).


430 **Organic synthesis of Advance Glycation End-products (AGEs)**

431 **N δ -(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine (MG-H1) (3)**



432
433 MG-H1 (**3**) was synthesized according to the literature procedure with a slight modification as
434 follows; (*L*)-Arginine (**1**) (6.07 g, 34.8 mmol, 1 equiv) was dissolved in 12 M HCl (50 mL). To this
435 was added methylglycol dimethyl acetal **2** (4.53 g, 38.3 mmol, 1.1 equiv). It was then stirred at
436 room temperature for 11 hrs. At this time, the reaction mixture was diluted with water (200 mL)
437 and concentrated *in vacuo*. The resulting dark-red solution was purified by SiO₂-gel column
438 chromatography (4:2:1 ethyl acetate:methanol:acetic acid) to give MG-H1 (**3**) as a yellow solid
439 (5.23 g, 22.9 mmol, 66%). The spectroscopic data obtained are consistent with those previously
440 reported in the literature [64].


441 **N ϵ -carboxymethyl-lysine (CML) (7a) and N ϵ -(1-carboxyethyl)-lysine (CEL) (7b)**



442
443 CML and CEL were synthesized according to the reported procedure [64] with a slight
444 modification; To a 25 mL flask was added N α -(*tert*-butoxycarbonyl)-*L*-lysine **4** (1.0 mmol, 1 equiv),
445 palladium on carbon (10 wt.% loading, 100 mg, 0.94 mmol), and distilled H₂O (7 mL). To this was
446 added glyoxylic acid (120 mg, 1.3 mmol, 1.3 equiv) for CML synthesis or pyruvic acid (115 mg,
447 1.3 mmol, 1.3 equiv) for CEL synthesis. 1N NaOH_(aq) was added dropwise to make pH of this
448 solution 9. A balloon filled with hydrogen gas was attached, and the resulting solution was stirred
449 at room temperature for 14 hrs. At this time, the reaction mixture was filtered through a celite pad

450 and the filtrate was concentrated *in vacuo*. Purification by SiO₂-gel column chromatography (1:2
451 ethyl acetate:methanol) yielded **6a** (260 mg, 0.85 mmol) or **6b** (263 mg, 0.83 mmol), respectively.
452 To this was added 1 N HCl_(aq) (3 mL), and it was then stirred at room temperature for 3 hrs. The
453 resulting solution was concentrated *in vacuo* to give CML **7a** (164 mg, 0.80 mmol, 80%) or CEL
454 **7b** (172 mg, 0.79 mmol, 79%). The spectroscopic data obtained are consistent with
455 those previously reported in the literature [64].

456 **Synthesis of F-ly (12)**



457
458 FLY (**12**) was synthesized according to the literature procedure with a slight modification
459 as follows; To a 200 mL round-bottomed flask was added Na-(*tert*-butoxycarbonyl)-L-lysine **4**
460 (510 mg, 2.8 mmol, 1 equiv), D-(+)-glucose (6.15 g, 30.0 mmol, 10 equiv), and MeOH (90 mL).
461 The condenser was attached, and it was refluxed for 7 hrs. After that, it was cooled to room
462 temperature and concentrated *in vacuo*. The generated solid residue was purified by reversed-
463 phase SiO₂-gel chromatography (H₂O only) to provide the desired compound **11** in 53% yield
464 (599 mg, 1.47 mmol). This compound was reacted with 1 N HCl(aq) (3.5 mL) at room
465 temperature and stirred overnight. After the concentration *in vacuo*, Fly **12** was obtained in 97%
466 yield (438 mg, 1.42 mmol). The spectroscopic data obtained are consistent with those
467 previously reported in the literature [65].

468 **Preparation of samples and methodology for RNAseq**

469 RNA preparation for RNAseq was performed using the Qiagen RNeasy Mini kit (Cat. No.
470 73404). Total RNA extraction was performed from thirty-day 1 adult animals picked and collected
471 in 20 μ l M9 buffer per condition. 5 biological replicates were used for wild-type N2 and mutant
472 animals. RNA-seq on the extracted total RNA was executed at the University of Minnesota
473 Genomics Core (UMGC) using their sequencing protocol for HiSeq 2500 High Output (HO) mode
474 and 50-bp Paired-end sequencing following Illumina Library Preparation. RNAseq coverage was
475 ~22 million reads per sample to perform downstream bioinformatics analyses.

476 **Bioinformatic analysis**

477 RNAseq global transcriptome data were subjected to Gene Ontology (GO) based
478 functional classification using the Database for Annotation, Visualization and Integrated Discovery
479 (DAVID) v.6.8. We employed the heatmap2 (Galaxy Version 3.0.1) function from R ggplot2
480 package to visualize the bioinformatics data.

481 HOMER (Hypergeometric Optimization of Motif EnRichment) analysis was used to identify
482 the transcription factors for the 66 differentially expressed gene from Figure 2B. A threshold of
483 18% was used to select potential transcription factors for further screening. Please refer to the
484 flow chart in Figure 3B.

485 **Reverse transcription polymerase chain reaction (RT-PCR)**

486 Total RNA was extracted from nearly 100 μ l of tightly packed age-synchronized adult worm pellet
487 collected in 1 ml TRIzol reagent provided by Qiagen RNeasy Mini kit (Cat. No. 73404) following
488 manufacturer's protocol. Subsequently, 1 μ g total RNA was used as a template for cDNA
489 synthesis. cDNA was synthesized using the iScriptTM cDNA synthesis kit (Bio-Rad, CA) following
490 the manufacturer's protocol. q-PCR was carried out using the PCR Biosystems Sygreen Blue Mix
491 Separat -ROX (Cat. No. 17-507DB) in a LightCycler 480 Real-Time PCR system (Roche
492 Diagnostics Corp., IN). Quantification was performed using the comparative $\Delta\Delta$ Ct method and

493 normalization for internal reference was done using either *act-5* or *pmp-2*. All assays were
494 performed with 3 technical replicates followed by 2-3 biological replicates. Following are qPCR
495 primers used: 1) *act-5* gene primers are “TTCCAATCTATGAAGGATATGCCCTCCC and
496 AAAGCTTCTCTTTGATGTCCCGGAC”. *pmp-2* primer pair is
497 “ATCTTTCAAAGCCAATCCTCGAC and GAGATAAGTCAGCCCAACTCC”. *glod-4*:
498 TGTTCTGAATATGAAAGTTCTTCGCCACG and
499 GATGACGATTGCTCTATAATCATTACCCAACCTC. *elt-3*:
500 GCCGTTCAATATTTTTGAATTGAACCTTTCAAACCTT and TTTTTTTCATCGGCTTCGGCTCG.
501 *tdc-1*: CGACGAGTTGTTCTGCTATT and CGGATGTTGCCAATGAGTTATT. *tyra-2*:
502 GGAAGAGGAGGAAGAAGATAGCGAAAGTAG and ATCTCGCTTTTCATCCGAGTCTTCATC.
503 *tyra-3*: CATCGATGGCCGCTTGGTC and CTTGTTCTCGGGTATTTGAGCGGT. *ser-2*:
504 GGAACAATTACGTACTTGGTAATTATTGCAATGAC and ATATCGCCACCGCCAGATCG. *snt*-
505 1: CGGAAGCAGTAAAGCAAATAGCAACAAC and
506 TCCCAGTTTGTTGCATAACCTTTTCTTTCA. And *daf-7*:
507 AGAGTACCTTAAGAACGAAATTCTCGACCA and
508 CCTTCTCCAGTAAGTCCCTATACATCTCC.

509 **Lifespan assay**

510 Lifespan assays were performed in Thermo Scientific Precision incubators at 20°C. Timed
511 egg laying was performed to obtain a synchronized animal population, which were either placed
512 onto NGM plates seeded with 5X concentrated *E. coli* OP50-1. Post-L4 stage or young adult
513 worms (60 to 65 hrs from egg laying) were added to FuDR (5-fluoro-2 deoxyuridine) NGM plates
514 to inhibit the development and growth of progeny. After three days, animals were transferred to a
515 new 60 mm NGM seeded with OP50-1 and scored every other day thereafter. 45-80 animals were
516 considered for each lifespan experiment, and 2-3 biological replicates were performed. Animal
517 viability was assessed visually and with gentle prodding on the head. Animals were censored in

518 the event of internal hatching of the larvae, body rupture, or crawling of larvae from the plates
519 [17].

520 **Assay for assessing neuronal damage**

521 Neuronal damage was assayed using a pan-neuronal GFP reporter strain under different
522 conditions on day 8 of adulthood. Animals were paralyzed using freshly prepared 5 mM
523 levamisole in M9 buffer and mounted on 2% agar pads under glass coverslips. Neuronal damage
524 was visually inspected under an upright Olympus BX51 compound microscope coupled with a
525 Hamatsu OcrA ER digital camera. Images were acquired under the 40X objective. Neuronal
526 deterioration was examined and characterized by loss of fluorescent intensity of nerve ring,
527 abnormal branching of axon/dendrite, and thinning and fragmentation of axons and neuronal
528 commissures [66]. Quantification and imaging of animals harboring damage were performed
529 using the Image J™ software (<http://imagej.nih.gov/ij/>). To reduce experimental bias, this assay
530 was performed genotype blind with 2 biological repeats.

531 **Statistical Analysis**

532 All data analyses for lifespan, pharyngeal pumping assays, and gene expression were
533 performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). Survival curves were
534 plotted using the Kaplan-Meier method, and a comparison between the survival curves to
535 measure significance (P values) was performed using Log-rank (Mantel-Cox) test. Two groups
536 were compared for significance using an unpaired Student's t -test. Multiple group comparison
537 was performed by one-way ANOVA with either Fisher's LSD or Dunnett's multiple comparisons
538 test, and Sidak's multiple comparisons test was used to compare between specific groups. P
539 values from the significance testing were designated as follows: * P <0.05, ** P <0.005 and
540 *** P <0.0005.

541 **Data and material availability**

542 All the data generated in this study are presented in the article. Synthetic AGEs can be
543 obtained upon request.

544

545 **AUTHORS CONTRIBUTIONS**

546 MMS, JC, and DS designed experiments, performed experiments, analyzed data, and wrote the
547 manuscript. AKS, SG, MC, and BH performed experiments and analyzed data. RS and CR
548 synthesized AGEs for the study. GL guided the study. PK conceived and guided the study,
549 designed experiments, and obtained funding for the study.

550

551 **ACKNOWLEDGEMENTS**

552 This work was supported by grants from NIH (R01AG061165 and R01AG068288) to PK and the
553 Larry L. Hillblom Foundation (2021-A-007-FEL) to PK. We thank Professors Keith Blackwell,
554 Suneil Koliwad, Malene Hansen and the members of the Kapahi lab for their valuable
555 suggestions. We thank Dr. Feimei Zhu for her guidance in troubleshooting the food clearance
556 assay. Dr. Kiyomi Kaneshiro for her guidance in organizing the RNAseq data. We also thank the
557 Buck Institute's morphology and imaging core for their valuable assistance.

558

559 **CONFLICT OF INTEREST**

560 Authors declare no conflict of interest.

561

562 **REFERENCE**

- 563 1. Chaudhuri, J., et al., *The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality*. Cell Metab, 2018. **28**(3): p. 337-352.
- 564
- 565 2. Nowotny, K., et al., *Dietary advanced glycation end products and their relevance for human health*. Ageing Res Rev, 2018. **47**: p. 55-66.
- 566
- 567 3. Zhang, Q., Y. Wang, and L. Fu, *Dietary advanced glycation end-products: Perspectives linking food processing with health implications*. Compr Rev Food Sci Food Saf, 2020. **19**(5): p. 2559-2587.
- 568
- 569 4. Maillard, L.C., *Action des Acides Amines sur les Sucres: Formation des Melanoidines par voie Methodique*. Comptes rendus de l'Académie des Sciences (Paris), 1912. **154**: p. 66-68.
- 570
- 571 5. H. Jaeger, A. Janositz, and D. Knorr, *The Maillard reaction and its control during food processing. The potential of emerging technologies*. Pathologie Biologie, 2009. **58**(3): p. 207-213.
- 572
- 573 6. Liu, X., et al., *Maillard conjugates and their potential in food and nutritional industries: A review*. Food Frontiers, 2020. **1**(4): p. 382-397.
- 574
- 575 7. Lima, M. and J.W. Baynes, *Glycation*, in *Encyclopedia of Biological Chemistry*. 2013. p. 405-411.
- 576 8. Machiels D and L. Istasse, *Maillard reaction: importance and applications in food chemistry*. Annales de Médecine Vétérinaire, 2022. **146**(6): p. 347-352.
- 577
- 578 9. Luca, F., G.H. Perry, and A. Di Rienzo, *Evolutionary adaptations to dietary changes*. Annu Rev Nutr, 2010. **30**: p. 291-314.
- 579
- 580 10. Donald S. Mottram, B.L. Wedzicha, and A.T. Dodson, *Acrylamide is formed in the Maillard reaction*. Nature, 2022. **419**: p. 448-449.
- 581
- 582 11. Richard H. Stadler, et al., *Acrylamide from Maillard reaction products*. Nature, 2002. **419**(449-450).
- 583
- 584 12. Allaman, I., M. Belanger, and P.J. Magistretti, *Methylglyoxal, the dark side of glycolysis*. Front Neurosci, 2015. **9**: p. 23.
- 585

- 586 13. Chen, J.H., et al., *Role of advanced glycation end products in mobility and considerations in*
587 *possible dietary and nutritional intervention strategies*. Nutr Metab (Lond), 2018. **15**: p. 72.
- 588 14. Vistoli, G., et al., *Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an*
589 *overview of their mechanisms of formation*. Free Radic Res, 2013. **47 Suppl 1**: p. 3-27.
- 590 15. He, Y., et al., *Glyoxalase system: A systematic review of its biological activity, related-diseases,*
591 *screening methods and small molecule regulators*. Biomed Pharmacother, 2020. **131**: p. 110663.
- 592 16. Distler, M.G. and A.A. Palmer, *Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior:*
593 *recent advances and mechanistic insights*. Front Genet, 2012. **3**: p. 250.
- 594 17. Chaudhuri, J., et al., *A Caenorhabditis elegans Model Elucidates a Conserved Role for TRPA1-Nrf*
595 *Signaling in Reactive alpha-Dicarbonyl Detoxification*. Curr Biol, 2016. **26**(22): p. 3014-3025.
- 596 18. Vincent M. Monnier, R.R.K., Anthony Cerami, *Accelerated age-related browning of human*
597 *collagen in diabetes mellitus*. PNAS, 1984. **81**: p. 583-587.
- 598 19. Samuel Rahbar, Olga Blumenfeld, and H.M. Ranney, *Studies of unusual hemoglobin in the patients*
599 *with diabetes mellitus*. Biochemical and biophysical research communications, 1969. **36**(5).
- 600 20. Ramasamy, R., et al., *Advanced glycation end products and RAGE: a common thread in aging,*
601 *diabetes, neurodegeneration, and inflammation*. Glycobiology, 2005. **15**(7): p. 16R-28R.
- 602 21. Prasad, C., et al., *Advanced Glycation End Products and Risks for Chronic Diseases: Intervening*
603 *Through Lifestyle Modification*. Am J Lifestyle Med, 2019. **13**(4): p. 384-404.
- 604 22. Lee, T.H. and S.Y. Yau, *From Obesity to Hippocampal Neurodegeneration: Pathogenesis and Non-*
605 *Pharmacological Interventions*. Int J Mol Sci, 2020. **22**(1).
- 606 23. Miller, A.A. and S.J. Spencer, *Obesity and neuroinflammation: a pathway to cognitive impairment*.
607 Brain Behav Immun, 2014. **42**: p. 10-21.
- 608 24. Wolin, K.Y., K. Carson, and G.A. Colditz, *Obesity and cancer*. Oncologist, 2010. **15**(6): p. 556-65.

- 609 25. Ellulu, M.S., et al., *Obesity and inflammation: the linking mechanism and the complications*. Arch
610 Med Sci, 2017. **13**(4): p. 851-863.
- 611 26. Keramat, S.A., et al., *Obesity and the risk of developing chronic diseases in middle-aged and older
612 adults: Findings from an Australian longitudinal population survey, 2009-2017*. PLoS One, 2021.
613 **16**(11): p. e0260158.
- 614 27. Uribarri, J., et al., *Elevated serum advanced glycation endproducts in obese indicate risk for the
615 metabolic syndrome: a link between healthy and unhealthy obesity?* J Clin Endocrinol Metab,
616 2015. **100**(5): p. 1957-66.
- 617 28. Ruhm, C.J., *Understanding overeating and obesity*. J Health Econ, 2012. **31**(6): p. 781-96.
- 618 29. Parvez Hossain, Bisher Kavar, and M.E. Nahas., *Obesity and diabetes in the developing world - A
619 growing challenge*. New England Journal of Medicine, 2007. **356**(3): p. 213 - 215.
- 620 30. Loos, R.J.F. and G.S.H. Yeo, *The genetics of obesity: from discovery to biology*. Nat Rev Genet,
621 2022. **23**(2): p. 120-133.
- 622 31. Dallièrè, N., et al., *Caenorhabditis elegans Feeding Behaviors*, in *Oxford Research Encyclopedia of
623 Neuroscience*. 2017.
- 624 32. Sandeep Golegaonkar, S.S.T., Awadhesh, et al., *Rifampicin reduces advanced glycation end
625 products and activates DAF-16 to increase lifespan in Caenorhabditis elegans*. Aging Cell, 2015.
626 **14**: p. 463-473.
- 627 33. Michael Morcos, et al., *Glyoxalase-1 prevents mitochondrial protein
628 modification and enhances lifespan in
629 Caenorhabditis elegans*. Aging Cell, 2008. **7**: p. 260-269.
- 630 34. Leon Avery and H.R. Horvitz, *Effects of starvation and neuroactive drugs on feeding in
631 Caenorhabditis elegans*. The Journal of Experimental Zoology, 1990. **253**: p. 263-270.

- 632 35. Chase, D.L. and M.R. Koelle, *Biogenic amine neurotransmitters in C. elegans*. WormBook, 2007: p.
633 1-15.
- 634 36. Trojanowski, N.F., D.M. Raizen, and C. Fang-Yen, *Pharyngeal pumping in Caenorhabditis elegans*
635 *depends on tonic and phasic signaling from the nervous system*. Sci Rep, 2016. **6**: p. 22940.
- 636 37. Gross, A.D., M.J. Kimber, and J.R. Coats, *G-Protein-Coupled Receptors (GPCRs) as Biopesticide*
637 *Targets: A Focus on Octopamine and Tyramine Receptors*, in *Biopesticides: State of the Art and*
638 *Future Opportunities*. 2014. p. 45-56.
- 639 38. Pirri, J.K., et al., *A tyramine-gated chloride channel coordinates distinct motor programs of a*
640 *Caenorhabditis elegans escape response*. Neuron, 2009. **62**(4): p. 526-38.
- 641 39. Mango, S.E., *The C. elegans pharynx: a model for organogenesis*. WormBook, 2007: p. 1-26.
- 642 40. Susan E. Mango, Eric J. Lambie, and J. Kimble, *The pha-4 gene is required to generate the*
643 *pharyngeal primordium of Caenorhabditis elegans*. Development, 1994. **120**: p. 3019-3031.
- 644 41. Ravichandran, M., et al., *Impairing L-Threonine Catabolism Promotes Healthspan through*
645 *Methylglyoxal-Mediated Proteohormesis*. Cell Metab, 2018. **27**(4): p. 914-925 e5.
- 646 42. Papaevgeniou, N., et al., *Sugar-derived AGEs accelerate pharyngeal pumping rate and increase*
647 *the lifespan of Caenorhabditis elegans*. Free Radic Res, 2019. **53**(sup1): p. 1056-1067.
- 648 43. Alkema, M.J., et al., *Tyramine Functions independently of octopamine in the Caenorhabditis*
649 *elegans nervous system*. Neuron, 2005. **46**(2): p. 247-60.
- 650 44. Greer, E.R., et al., *Neural and molecular dissection of a C. elegans sensory circuit that regulates fat*
651 *and feeding*. Cell Metab, 2008. **8**(2): p. 118-31.
- 652 45. Rex, E., et al., *Tyramine receptor (SER-2) isoforms are involved in the regulation of pharyngeal*
653 *pumping and foraging behavior in Caenorhabditis elegans*. J Neurochem, 2004. **91**(5): p. 1104-15.
- 654 46. Li, Z., et al., *Dissecting a central flip-flop circuit that integrates contradictory sensory cues in C.*
655 *elegans feeding regulation*. Nat Commun, 2012. **3**: p. 776.

- 656 47. Rex, E., et al., *TYRA-2 (F01E11.5): a Caenorhabditis elegans tyramine receptor expressed in the MC*
657 *and NSM pharyngeal neurons*. J Neurochem, 2005. **94**(1): p. 181-91.
- 658 48. Tsalik, E.L., et al., *LIM homeobox gene-dependent expression of biogenic amine receptors in*
659 *restricted regions of the C. elegans nervous system*. Developmental Biology, 2003. **263**(1): p. 81-
660 102.
- 661 49. Bierhaus, A., et al., *Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and*
662 *causes hyperalgesia in diabetic neuropathy*. Nat Med, 2012. **18**(6): p. 926-33.
- 663 50. Rabbani, N. and P.J. Thornalley, *Measurement of methylglyoxal by stable isotopic dilution analysis*
664 *LC-MS/MS with corroborative prediction in physiological samples*. Nat Protoc, 2014. **9**(8): p. 1969-
665 79.
- 666 51. Kold-Christensen, R., et al., *ReactELISA method for quantifying methylglyoxal levels in plasma and*
667 *cell cultures*. Redox Biol, 2019. **26**: p. 101252.
- 668 52. Ismail, L., H. Materwala, and J. Al Kaabi, *Association of risk factors with type 2 diabetes: A*
669 *systematic review*. Comput Struct Biotechnol J, 2021. **19**: p. 1759-1785.
- 670 53. John S. Gilleard, Y.S., J. David Barry, James D. McGhee, *ELT-3: A Caenorhabditis elegans GATA*
671 *factor expressed in the embryonic epidermis during morphogenesis*. Developmental Biology, 1999.
672 **208**: p. 265-280.
- 673 54. Shobatake, R., et al., *Up-regulation of POMC and CART mRNAs by intermittent hypoxia via GATA*
674 *transcription factors in human neuronal cells*. Int J Biochem Cell Biol, 2018. **95**: p. 100-107.
- 675 55. Jaime Uribarri, et al., *Advanced glycation end products in foods and a practical guide to their*
676 *reduction in the diet*. J Am Diet Assoc. , 2011. **110**(6): p. 911-16.
- 677 56. Aiello, M., V. Silani, and R.I. Rumiati, *You stole my food! Eating alterations in frontotemporal*
678 *dementia*. Neurocase, 2016. **22**(4): p. 400-409.


- 679 57. Perez-Gomez, A., et al., *A phenotypic Caenorhabditis elegans screen identifies a selective*
680 *suppressor of antipsychotic-induced hyperphagia*. Nat Commun, 2018. **9**(1): p. 5272.
- 681 58. Vicente Miranda, H., et al., *Glycation potentiates alpha-synuclein-associated neurodegeneration*
682 *in synucleinopathies*. Brain, 2017. **140**(5): p. 1399-1419.
- 683 59. Muddapu, V.R., et al., *Neurodegenerative Diseases - Is Metabolic Deficiency the Root Cause?* Front
684 Neurosci, 2020. **14**: p. 213.
- 685 60. Procaccini C., S.M., Faicchia D., Colamatteo A., Formisano L., De Candia P., Galgani M. , De Rose
686 V., Matarese G., *Role of metabolism in neurodegenerative disorders*. Metabolism: Clinical and
687 Experimental, 2016. **65**(9): p. 1376-1390.
- 688 61. Raizen, D., et al., *Methods for measuring pharyngeal behaviors*. WormBook, 2012: p. 1-13.
- 689 62. Wu, Z., et al., *Dietary Restriction Extends Lifespan through Metabolic Regulation of Innate*
690 *Immunity*. Cell Metab, 2019. **29**(5): p. 1192-1205 e8.
- 691 63. Nyamsuren, O., et al., *A mutation in CHN-1/CHIP suppresses muscle degeneration in*
692 *Caenorhabditis elegans*. Dev Biol, 2007. **312**(1): p. 193-202.
- 693 64. Michael Hellwig, et al., *Transport of free and peptide-bound glycated amino acids: Synthesis,*
694 *transepithelial flux at Caco-2 cell monolayers, and interaction with apical membrane transport*
695 *proteins*. ChemBioChem, 2011. **12**(8): p. 1270-1279.
- 696 65. Paul J. Thornalley, nAnnika Langborg, and H.S. Minhas, *Formation of glyoxal, methylglyoxal and*
697 *3-deoxyglucosone in the glycation of proteins by glycose*. Biochem. J. , 199. **344**: p. 109-116.
- 698 66. Bijwadia, S.R., K. Morton, and J.N. Meyer, *Quantifying Levels of Dopaminergic Neuron*
699 *Morphological Alteration and Degeneration in Caenorhabditis elegans*. J Vis Exp, 2021(177).

700

701

702 **SUPPLEMENTAL FIGURES**


703 Figure 1 - Figure supplemental 1:



704

705 Figure 1 - Figure Suppl. 1: (A) Food clearance assay demonstrating increased food intake with
 706 an increasing number of worms. (B & C) Food clearance assay of wild-type N2 and *glod-4* (*gk189*)
 707 mutant with 5 mM treatment of serotonin, respectively. (D) Quick visual quantification of
 708 pharyngeal pumping after treatment with different AGEs molecules at 100 μ M for 12-18 hours.
 709 (E) Quantification of pharyngeal pumping in N2 (wt) worms after treatment with phosphate-
 710 buffered saline or 150 μ M of Arginine for 24 hours. (F) Pictorial representation of food racing
 711 assay. Student's t-test for B+C. One-way ANOVA for A+D. * p < 0.05, ** p < 0.01, *** p < 0.005 and
 712 **** p < 0.0001. Error bar \pm SD.


713 Figure 2 - Figure supplemental 2:



714

715 Figure 2 - Figure Suppl. 2: (A) Quantification of pharyngeal pumping (quick screening by visual
 716 counting) on mutants of enzymes involved in the biosynthesis of biogenic amines after MG-H1
 717 treatment (suppressor screen). (B) Quantification of pharyngeal pumping (quick screening by
 718 visual counting) on receptor mutants involved in feeding behavior after MG-H1 treatment.
 719 Student's t-test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$ and **** $p < 0.0001$. Error bar \pm SD.

720 Figure 3 - Figure supplemental 3:



B

Gene Name	Gene Description	ELT-3(GATA)/C. elegans-L1-ELT3-ChIP-Seq(modEncode) / Homer Distance From Peak (sequence, strand, conservation)
<i>snt-1</i>	SyNapTotagmin	-4606(TCATATCATC,-,0.00),-2694(TCTTATCTGA,-,0.00),-763(TATTATCATT,-,0.00)
<i>unc-7</i>	Innexin	-2575(AATGATAACA,+,0.00),-2146(TTTTATCAAA,-,0.00),-1070(TCATATCACA,-,0.00)
<i>egl-19</i>	hypothetical protein	-1740(TAAGATAAGA,+,0.00),-24(AATGATAAGT,+,0.00)
<i>daf-7</i>	Dauer larva development regulatory growth factor daf-7	-1132(TCTTATCAAC,-,0.00),-801(TTTTATCAGA,-,0.00),-617(GTTGATAACA,+,0.00)
<i>egl-30</i>	hypothetical protein	None
<i>eat-18</i>	hypothetical protein	None
<i>tdc-1</i>	Tyrosine decarboxylase	-3870(GTTGATAAGG,+,0.00),-3832(ACTGATAAGA,+,0.00),-263(TCTTATCATT,-,0.00)
<i>unc-13</i>	Phorbol ester/diacylglycerol-binding protein unc-13	-2638(TTTTATCAAT,-,0.00),-1657(TTTGATATGA,+,0.00)

721

722 Figure 3 - Figure Suppl. 3: (A) Quantification of pharyngeal pumping (Quick visual counting),
 723 suppressor screen for top 5 transcription factors listed in Figure 3A. (B) List of genes obtained by
 724 HOMER analysis that are potentially regulated by the *elt-3* transcription factor. Student t-test in
 725 A. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$ and **** $p < 0.0001$. Error bar \pm SD.